Literature DB >> 15127423

When does quality-adjusting life-years matter in cost-effectiveness analysis?

Richard H Chapman1, Marc Berger, Milton C Weinstein, Jane C Weeks, Sue Goldie, Peter J Neumann.   

Abstract

PURPOSE: This paper investigates the impact of quality-of-life adjustment on cost-effectiveness analyses, by comparing ratios from published studies that have reported both incremental costs per (unadjusted) life-year and per quality-adjusted life-year for the same intervention.
METHODS: A systematic literature search identified 228 original cost-utility analyses published prior to 1998. Sixty-three of these analyses (173 ratio pairs) reported both cost/LY and cost/QALY ratios for the same intervention, from which we calculated medians and means, the difference between ratios (cost/LY minus cost/QALY) and between reciprocals of the ratios, and cost/LY as a percentage of the corresponding cost/QALY ratio. We also compared the ratios using rank-order correlation, and assessed the frequency with which quality-adjustment resulted in a ratio crossing the widely used cost-effectiveness thresholds of 20, 000 US dollars, 50,000 US dollars, and 100,000 US dollars/QALY or LY.
RESULTS: The mean ratios were 69,100 US dollars/LY and 103,100 US dollars/QALY, with corresponding medians of 24,600 US dollars/LY and 20,400 US dollars/QALY. The mean difference between ratios was approximately -34,300 US dollars (median difference: 1300 US dollars), with 60% of ratio pairs differing by 10,000 US dollars/year or less. Mean difference between reciprocals was 59 (QA)LYs per million dollars (median: 2.1). The Spearman rank-order correlation between ratio types was 0.86 (p<0.001). Quality-adjustment led to a ratio moving either above or below 50,000 US dollars/LY (or QALY) in 8% of ratio pairs, and across 100,000 US dollars in 6% of cases.
CONCLUSIONS: In a sizable fraction of cost-utility analyses, quality adjusting did not substantially alter the estimated cost-effectiveness of an intervention, suggesting that sensitivity analyses using ad hoc adjustments or 'off-the-shelf' utility weights may be sufficient for many analyses. The collection of preference weight data should be subjected to the same scrutiny as other data inputs to cost-effectiveness analyses, and should only be under-taken if the value of this information is likely to be greater than the cost of obtaining it. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2004        PMID: 15127423     DOI: 10.1002/hec.853

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  28 in total

1.  How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions?

Authors:  Bruce R Schackman; Heather Taffet Gold; Patricia W Stone; Peter J Neumann
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  Cost-effectiveness analysis of a low-fat diet in the prevention of breast and ovarian cancer.

Authors:  Antônio M Bós; Barbara V Howard; Shirley A A Beresford; Nicole Urban; Lesley F Tinker; Hugh Waters; Angelo J Bós; Rowan Chlebowski; Jacqueline M Ennis
Journal:  J Am Diet Assoc       Date:  2011-01

3.  Measuring preferences for cost-utility analysis: how choice of method may influence decision-making.

Authors:  Christine M McDonough; Anna N A Tosteson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 4.  A systematic review of the key indicators for assessing telehomecare cost-effectiveness.

Authors:  Stephanie Vergara Rojas; Marie-Pierre Gagnon
Journal:  Telemed J E Health       Date:  2008-11       Impact factor: 3.536

Review 5.  The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications.

Authors:  José Manuel Rodríguez Barrios; Ferran Pérez Alcántara; Carlos Crespo Palomo; Paloma González García; Enrique Antón De Las Heras; Max Brosa Riestra
Journal:  Eur J Health Econ       Date:  2011-06-10

Review 6.  Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review.

Authors:  Patricia R Blank; Konstantin J Dedes; Thomas D Szucs
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

7.  Surgical treatment for adult spinal deformity: projected cost effectiveness at 5-year follow-up.

Authors:  Jamie Terran; Brian J McHugh; Charla R Fischer; Baron Lonner; Daniel Warren; Steven Glassman; Keith Bridwell; Frank Schwab; Virginie Lafage
Journal:  Ochsner J       Date:  2014

8.  Predicting health utilities for children with autism spectrum disorders.

Authors:  Nalin Payakachat; J Mick Tilford; Karen A Kuhlthau; N Job van Exel; Erica Kovacs; Jayne Bellando; Jeffrey M Pyne; Werner B F Brouwer
Journal:  Autism Res       Date:  2014-09-25       Impact factor: 5.216

Review 9.  Contemporary quality of life issues affecting gynecologic cancer survivors.

Authors:  Jeanne Carter; Richard Penson; Richard Barakat; Lari Wenzel
Journal:  Hematol Oncol Clin North Am       Date:  2011-12-16       Impact factor: 3.722

10.  Decision Analysis and Cost-effectiveness Analysis.

Authors:  Hilary F Ryder; Christine McDonough; Anna N A Tosteson; Jon D Lurie
Journal:  Semin Spine Surg       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.